NIIM Research
At the National Institute of Integrative Medicine (NIIM), we offer Circulating Tumour Cells (CTC) screening—a revolutionary blood test that has delivered remarkable results in cancer detection and monitoring.
CTCs are well-established cancer biomarkers, referenced in 26,000 peer-reviewed articles, which assist with early cancer detection and assessment of treatment effectiveness. Unlike many traditional tests, the CTC test can detect ANY cancer cells from ANY type of cancer.
At NIIM, we utilize the ISET-CTC test, a cytology-based (microscopy) method widely regarded as the gold standard in oncology testing, with very high accuracy.
NIIM’s CTC cancer screening test includes additional testing specific for prostate or breast cancer.
For men, the improved prostate cancer screening test combines the CTC test with the PSA marker (marker=antigen=specific protein on the surface of the cancer cell) which has higher accuracy than the PSA blood test.
While the traditional PSA blood test has an accuracy rate of just 15-25%, NIIM’s combined approach achieves an impressive 97-99% accuracy, significantly improving early detection rates and reducing the risks of false positives or missed diagnoses.
For women, the combination of CTC test and a breast marker (Mammaglobin) provides a high sensitivity and specificity, with an overall accuracy of approximately 80%.
Caption: CTC with positive breast marker staining
To learn more about the CTC test or to book a screening, visit http://niim.com.au/research/ctc or contact NIIM at research@niim.com.au .
